The trademark application FAZAMBIQ was filed by Regeneron Pharmaceuticals, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on April 26, 2020, and it was registered by office on August 4, 2020 without any oppositions.
The application was filed in English (German was selected as the second language).